- Disease: Acute SARS-CoV-2
- Study type: Observational Cohort Study
- Study type descriptors: Prospective, Single centre
- Study aim: To assess the efficacy of early combination treatment with one antiviral and a monoclonal antibody, presumably active against the circulating SARS-CoV-2 variant, in non-hospitalized immunocompromised outpatients with mild-to-moderate COVID-19
- Number of participants enrolled: 52
- Study enrolling from to
- Study includes follow-up for 3 months
Study Data
- Adults
- General population
- Elderly
- Fragile population
- Hospital wide
- Emergency department
- SARS-CoV-2
- Acute SARS-CoV-2
- Pharmacological intervention
- Antivirals
- Remdesivir
- Monoclonal antibodies
- Nirmatrelvir/Ritonavir
- Sotrovimab
External Links
Other information
Funders:
- NextGenerationeU-MUR PNRR extended Partnership initiative on emerging infectious Diseases
If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it
The data is updated up to